RxDoctor Payments Data

Sharon Werner, MD

Family Medicine · Baton Rouge, LANPI 1144242983

Payments from drug & device makers

$235in general payments, 2019–2025

Across 16 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$48
  • Lilly USA, LLC$46
  • AbbVie$26
  • Novartis$19
  • Novo Nordisk$16
  • GSK$15
  • plus $65 from 6 others

What the payments were for

  • Food & beverage$235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$235 in reported general payments places this provider in the 30th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,299
Medicare patients
26
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$206,615
JardianceEmpagliflozin118$177,482
TrulicityDulaglutide53$89,701
MounjaroTirzepatide29$44,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$27,151
JanuviaSitagliptin Phosphate22$27,089
EliquisApixaban29$26,940
FarxigaDapagliflozin Propanediol27$22,549
Tresiba Flextouch U-100Insulin Degludec14$15,224
Lantus SolostarInsulin Glargine,hum.Rec.Anlog121$15,009
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$12,820
Incruse ElliptaUmeclidinium Bromide16$12,588
Novolog FlexpenInsulin Aspart61$12,009
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$10,922
Victoza 2-PakLiraglutide14$10,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$206,615117 claims
Lilly USA, LLCTrulicity, Mounjaro$46$133,94382 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arexvy$15$68,914119 claims
AstraZenecaFarxiga, Symbicort$13$33,11256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →